Under the terms of the agreement Aslan will pay a transfer price for the bulk product which is dependent on the specified concentration of human lactoferrin product (hLF).
The agreement has a lifetime of five years with an option to further extension. During the initial period of the agreement Pharming’s production capacity will be increased to be able to satisfy the growing market’s demand.
Under the agreement, Pharming will supply to Aslan milk powder containing specified amounts of hLF. Aslan will be responsible for the production and the design of the finished products. The final products will be used as food or as a food supplement targeted at people who will benefit from the use of hLF. Aslan acquired the exclusive distribution rights for Turkey, Middle East, Ukraine and Russia.
Lactoferrin is a protein naturally present in different mammalian secretions especially in human breast milk, saliva and tears. The protein is said to possess several properties related to the human immune system, including anti-infective and anti-inflammatory protection. Pharming is producing hLF in milk of transgenic cattle in its facilities in Wisconsin (US) for use as an ingredient in advanced nutritional products.